Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
Augūnaitė, Laura, Jakinevičiūtė, Miglė, Šnipaitienė, Aušra, Jankauskaitė, Lina
Abstract
flares.Eleven serious infections were reported in nine patients (pneumonia (n=3), one each: anal abscess, appendicitis, bronchitis, herpes virus infection, influenza, orchitis, pyelonephritis and tonsillitis).Conclusion: Canakinumab proved effective to control disease activity and prevent flares in MKD during the 72-week study period.Individual dose adjustments may be required to maintain the therapeutic effect of canakinumab.No new or unexpected safety concerns were reported.
Topics & Concepts
MedicineRheumatologyInternal medicineFamily medicineAutoimmune and Inflammatory Disorders ResearchInflammasome and immune disordersPediatric health and respiratory diseases